31 March 2026
Nuformix plc
("Nuformix" or the "Company")
Total Voting Rights
Following the issue of new ordinary shares of 0.05p each in the Company ("Ordinary Shares") pursuant to the placing, as announced on 11 March 2026, the Company is today providing a confirmation regarding its voting rights, in line with section DTR 5.6.1 of the FCA's Disclosure Guidance and Transparency Rules sourcebook.
As of the date of this announcement, the Company's issued ordinary share capital consists of 2,609,749,903 Ordinary Shares, each with one voting right. The Company does not hold any Ordinary Shares in treasury. The total voting rights figure is therefore 2,609,749,903 and this can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change of their interest in, the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.
Enquiries:
|
Nuformix plc |
|
|
Dr Dan Gooding, Executive Director |
Via IFC Advisory |
|
CMC Markets |
|
|
Douglas Crippen |
+44 (0) 20 3003 8632 |
|
IFC Advisory Limited |
|
|
Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6632 nuformix@investor-focus.co.uk |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.